Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

248.82

-4.22 (1.67%)

as of Jul 20, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Jul 20, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has faced challenges in its cardio business, but experts are generally optimistic about its future, especially following a recent earnings report. The company is transitioning into a pharmaceutical pure-play after spinning off its orthopedics division, which has helped bolster its position in higher-margin sectors such as medical devices and pharmaceuticals. Many analysts believe that despite past legal issues related to talcum powder lawsuits, these concerns have diminished and are unlikely to significantly impact the stock's future performance. With a strong pipeline of drugs, particularly in oncology, JNJ's stock is seen as a promising investment, especially for dividend growth. Overall, the sentiment indicates that buyers may want to capitalize on potential weakness in the stock.

Consensus

Buy

Valuation

Fair Value

Similar

P&GA,PG

TOP PICK

2.5% dividend. Gives you US exposure if you need that. Very defensive in terms of the drug companies. Not highly leveraged. Very good product mix. A defensive holding.

BUY

Stock gives you a split between consumer products, medical devices and pharmaceuticals. Pharmaceuticals are weak because of patents coming off. Medical device sector will face higher competition. Want to use cash from the consumer products for R&D. Dividends have gone up recently. Won't give you great growth, but a good conservative holding. Only buy 1/2 a position now and add more later.

TOP PICK

Has gone down over the last number of years from its peak. Trading at 15 X next year's earnings. Really a closed end fund of health care business. Good long-term hold. Ultimately, the market will value it for its good cash flow.

BUY

Gives investors good diversification in 3 pharmaceutical type products drugs, medical devices and consumer products. Nice steady growth in all three. Revenue growth has been languishing which is why the stock has not moved up.

PAST TOP PICK

(A Top Pick Feb 9/06. No change.) This was his insurance in case things got a little rocky. Still likes.

BUY

Has suffered from a lot that is happening in the pharmaceutical area. Pharmaceutical stocks are some of the cheapest around. A good solid company and if you have a long-term approach, it's a good buy here.

WATCH

They like it because of their cardiac care, health and beauty products. They are not crazy about the patented medicine part of the company. It is nicely positioned in the market. It has had a bit of a rocky road downhill. They are reviewing it and may be getting out.

DON'T BUY

Think the worst is over for the pharmaceutical industry. J & J is also into medical devices, and consumer products. The stock had been outperforming other pharmaceutical but now the others are outperforming J & J. He likes Phiser, and Teva Pharmaceutical.

SELL

Has been mispriced. Due for a correction

TOP PICK

Has had a rough go since last March. Trading at around 16 X earnings. Have $14 billion in cash and generate $1 billion in cash each month. Thinks it has bottomed out.

WAIT

He has a model price of $55.63 which is a negative differential of about 2%. It has to finish its downward run. He would wait until about $48.75/49 before buying.

TOP PICK

They were fighting with Boston Scientific (BSX-N) for an acquisition and lost. However, Boston Scientific has acquired a company larger than itself and will have to take on enormous debt and historically, these have turned out to be crippling deals.

BUY

Stock is down 9% over last year. All the big US pharmas are off a lot and this was the last one to fall. It has the best product range and does a very good job. He continues to like it.

DON'T BUY

Seening a little more strength on the pharmaceutical side. He would still prefer to go to the generics.

BUY

Finds the valuation a little bit high relative to the growth rate. A strong brand name. You can buy this and put it away for a number of years. Very low risk.

Showing 556 to 570 of 628 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)